The present invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics that mimic the biological activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 mimics exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration.
本发明提供了新型的人类胰高血糖素样肽-1 (GLP-1) 肽类模拟物,这些模拟物模仿了天然的 GLP-1 肽的
生物活性,因此可用于治疗或预防与 GLP 活性相关的疾病或疾病。此外,本发明提供了新型的
化学修饰肽,这些肽不仅可以刺激 II 型糖尿病患者的
胰岛素分泌,还可以产生其他有益的
胰岛素促进反应。这些合成的 GLP-1 模拟物肽类表现出对
蛋白酶水解的稳定性增加,使它们成为口服或静脉注射治疗的理想候选药物。